Hospira's average Accounts Receivable for the
three
months ended in Jun. 2015 was €537 Mil. Hospira's Revenue for the
three
months ended in Jun. 2015 was €1,055 Mil.
Hence, Hospira's Days Sales Outstanding for the
three
months ended in Jun. 2015 was 46.48.
The historical rank and industry rank for Hospira's Days Sales Outstanding or its related term are showing as below:
FRA:HOS'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.46 Med: 54.37 Max: 59.38
Current: 46.3
During the past 13 years, Hospira's highest Days Sales Outstanding was 59.38. The lowest was 45.46. And the median was 54.37.
FRA:HOS's Days Sales Outstanding is not ranked
in the Drug Manufacturers industry.
Industry Median: 71.845
vs FRA:HOS: 46.30
Hospira's Days Sales Outstanding
declined
from Jun. 2014 (48.02) to Jun. 2015 (46.48).
Hospira Days Sales Outstanding Historical Data
The historical data trend for Hospira's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Hospira's Days Sales Outstanding
For the Drug Manufacturers - Specialty & Generic subindustry, Hospira's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hospira's Days Sales Outstanding Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hospira's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Hospira's Days Sales Outstanding falls into.
Hospira Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hospira (FRA:HOS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Hospira Days Sales Outstanding Related Terms
Thank you for viewing the detailed overview of Hospira's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Hospira Inc was incorporated in Delaware on September 16, 2003. The Company is a provider of injectable drugs and infusion technologies, and is also engaged in developing, manufacturing, marketing and distribution. Its portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. The Company's business segments are Specialty Injectable Pharmaceuticals, Medication Management and Other Pharmaceuticals. Specialty Injectable Pharmaceuticals consists of generic injectable pharmaceuticals products. Generic injectable pharmaceuticals provide customers with a lower-cost alternative to branded products when associated patent protection expires, when patents are declared invalid, or when the generic products do not infringe the patents of others. Our generic injectable pharmaceuticals are sold in therapeutic areas including analgesia, anesthesia, anti-infectives, cardiovascular, oncology, and other. Medication Management offer the Hospira MedNet safety software system, which is designed for hospitals to customize intravenous drug dosage limits and track drug delivery to prevent medication errors. The wireless network version of the Hospira MedNet system establishes real-time send-and-receive capability and can interface with select hospital and pharmacy information systems. Other Pharmaceuticals primarily consists of large volume I.V. solutions, nutritionals and contract manufacturing services. We offer infusion therapy solutions and related supplies that include I.V. solutions for general use, I.V. nutrition products, and solutions for washing and cleansing of wounds or surgical sites. The Company's primary customers include hospitals, wholesalers, integrated delivery networks and alternate site facilities. Its competitors include Baxter International Inc.; Becton, Dickinson and Company; Fresenius Kabi AG; Mallinckrodt plc; Mylan Inc; Par Pharmaceuticals Companies, Inc.; Pfizer Inc.; Sandoz; Sanofi S.A. and Teva Pharmaceuticals, Aspen Medical; Fresenius Kabi; Pfizer; Sandoz and a number of smaller competitors and the originator companies. The Company's operations and business activities are subject to extensive legal and regulatory requirements that are enforced by numerous governmental agencies in the countries in which it do business.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:HOS has been successfully added to your 